Loading…

Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open-Label Titration Studies

Objective:  This analysis was conducted to determine the likelihood of identifying an effective dose of fentanyl sublingual tablet during the initial titration phase of 2 clinical trials, to characterize the actual effective dose in patients achieving successful titration, and to examine the relatio...

Full description

Saved in:
Bibliographic Details
Published in:Pain practice 2012-07, Vol.12 (6), p.449-456
Main Authors: Nalamachu, Srinivas R., Rauck, Richard L., Wallace, Mark S., Hassman, David, Howell, Julian
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4075-1c8079d3fc79cd5c71a119642d070cc38899a5d789985836f3b39c7f2da86193
cites cdi_FETCH-LOGICAL-c4075-1c8079d3fc79cd5c71a119642d070cc38899a5d789985836f3b39c7f2da86193
container_end_page 456
container_issue 6
container_start_page 449
container_title Pain practice
container_volume 12
creator Nalamachu, Srinivas R.
Rauck, Richard L.
Wallace, Mark S.
Hassman, David
Howell, Julian
description Objective:  This analysis was conducted to determine the likelihood of identifying an effective dose of fentanyl sublingual tablet during the initial titration phase of 2 clinical trials, to characterize the actual effective dose in patients achieving successful titration, and to examine the relationship between baseline characteristics and likelihood of achieving an effective dose. Methods:  Data were derived from 2 clinical trials (Study 1, n = 131; Study 2, n = 139) of fentanyl sublingual tablet in patients with cancer‐associated breakthrough pain (BTP). Both trials comprised a 2‐week titration phase and 12‐month maintenance phase. The initial dose was 100 μg, titrated to an effective dose (producing effective relief of all BTP episodes on 2 consecutive days) of 100 to 800 μg. Results:  A total of 270 patients entered the titration phase. Mean (SD) baseline BTP opioid dose was 25.7 (88.9) mg morphine equivalent, and mean baseline around‐the‐clock opioid dose was 196.5 (151.6) mg morphine equivalent. Using conservative criteria for determining effective dose, 174 patients (64.4%) were successfully titrated to an effective dose (mean [SD], 498.2 [234.8] μg). The most frequent (27.6%) effective dose was 800 μg, and more than 85% of patients required an effective dose ≥ 300 μg. There were no significant relationships between any baseline characteristics and titration success. Conclusion:  Despite stringent criteria, 64.4% of patients achieved an effective dose of fentanyl sublingual tablet within the dose range of 100 to 800 μg. Baseline characteristics were not identified to be associated with the likelihood of successful titration or with the actual effective dose of fentanyl sublingual tablet.
doi_str_mv 10.1111/j.1533-2500.2011.00525.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023533473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1023533473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4075-1c8079d3fc79cd5c71a119642d070cc38899a5d789985836f3b39c7f2da86193</originalsourceid><addsrcrecordid>eNqNkMFu1DAQhi0EoqXwCshHLgl2HMcJEodqYVukiFbdFUhcLMeegBcn2ca2uvv29XbLnpnLjOXvn5E-hDAlOU31cZNTzlhWcELyglCaE8ILnu9eoPPTx8unmWSC1PwMvfF-QwgVDWOv0VmRqmKCnqNhFbUG7_vo8JfJA17a0djxN36w4Q9exc6lR1QOL2EMatw7vFadg_AJL6ahsyMYfAc-uuBxP08DLvDNFsasVR0k1IZZBTuNeBWiseDfole9ch7ePfcLtF5-XS-us_bm6tviss10SQTPqK6JaAzrtWi04VpQRWlTlYUhgmjN6rppFDcitZrXrOpZxxot-sKouqINu0Afjmu383QfwQc5WK_BOTXCFL2kpGBJUylYQusjqufJ-xl6uZ3toOZ9guTBtdzIg1J5UCoPruWTa7lL0ffPV2I3gDkF_8lNwOcj8GAd7P97sby9vL1LU8pnx7z1AXanvJr_ykowweXP71fy16ptSfmjlJQ9AiZ1m3U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1023533473</pqid></control><display><type>article</type><title>Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open-Label Titration Studies</title><source>Wiley</source><creator>Nalamachu, Srinivas R. ; Rauck, Richard L. ; Wallace, Mark S. ; Hassman, David ; Howell, Julian</creator><creatorcontrib>Nalamachu, Srinivas R. ; Rauck, Richard L. ; Wallace, Mark S. ; Hassman, David ; Howell, Julian</creatorcontrib><description>Objective:  This analysis was conducted to determine the likelihood of identifying an effective dose of fentanyl sublingual tablet during the initial titration phase of 2 clinical trials, to characterize the actual effective dose in patients achieving successful titration, and to examine the relationship between baseline characteristics and likelihood of achieving an effective dose. Methods:  Data were derived from 2 clinical trials (Study 1, n = 131; Study 2, n = 139) of fentanyl sublingual tablet in patients with cancer‐associated breakthrough pain (BTP). Both trials comprised a 2‐week titration phase and 12‐month maintenance phase. The initial dose was 100 μg, titrated to an effective dose (producing effective relief of all BTP episodes on 2 consecutive days) of 100 to 800 μg. Results:  A total of 270 patients entered the titration phase. Mean (SD) baseline BTP opioid dose was 25.7 (88.9) mg morphine equivalent, and mean baseline around‐the‐clock opioid dose was 196.5 (151.6) mg morphine equivalent. Using conservative criteria for determining effective dose, 174 patients (64.4%) were successfully titrated to an effective dose (mean [SD], 498.2 [234.8] μg). The most frequent (27.6%) effective dose was 800 μg, and more than 85% of patients required an effective dose ≥ 300 μg. There were no significant relationships between any baseline characteristics and titration success. Conclusion:  Despite stringent criteria, 64.4% of patients achieved an effective dose of fentanyl sublingual tablet within the dose range of 100 to 800 μg. Baseline characteristics were not identified to be associated with the likelihood of successful titration or with the actual effective dose of fentanyl sublingual tablet.</description><identifier>ISSN: 1530-7085</identifier><identifier>EISSN: 1533-2500</identifier><identifier>DOI: 10.1111/j.1533-2500.2011.00525.x</identifier><identifier>PMID: 22226371</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Sublingual ; Adult ; Aged ; Aged, 80 and over ; analgesics ; Analgesics, Opioid - therapeutic use ; Breakthrough Pain - drug therapy ; Breakthrough Pain - etiology ; cancer ; Dose-Response Relationship, Drug ; Female ; Fentanyl - therapeutic use ; Humans ; Male ; Middle Aged ; Neoplasms - complications ; opioid ; Tablets - therapeutic use ; Treatment Outcome</subject><ispartof>Pain practice, 2012-07, Vol.12 (6), p.449-456</ispartof><rights>2012 The Authors. Pain Practice © 2012 World Institute of Pain</rights><rights>2012 The Authors. Pain Practice © 2012 World Institute of Pain.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4075-1c8079d3fc79cd5c71a119642d070cc38899a5d789985836f3b39c7f2da86193</citedby><cites>FETCH-LOGICAL-c4075-1c8079d3fc79cd5c71a119642d070cc38899a5d789985836f3b39c7f2da86193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22226371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nalamachu, Srinivas R.</creatorcontrib><creatorcontrib>Rauck, Richard L.</creatorcontrib><creatorcontrib>Wallace, Mark S.</creatorcontrib><creatorcontrib>Hassman, David</creatorcontrib><creatorcontrib>Howell, Julian</creatorcontrib><title>Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open-Label Titration Studies</title><title>Pain practice</title><addtitle>Pain Pract</addtitle><description>Objective:  This analysis was conducted to determine the likelihood of identifying an effective dose of fentanyl sublingual tablet during the initial titration phase of 2 clinical trials, to characterize the actual effective dose in patients achieving successful titration, and to examine the relationship between baseline characteristics and likelihood of achieving an effective dose. Methods:  Data were derived from 2 clinical trials (Study 1, n = 131; Study 2, n = 139) of fentanyl sublingual tablet in patients with cancer‐associated breakthrough pain (BTP). Both trials comprised a 2‐week titration phase and 12‐month maintenance phase. The initial dose was 100 μg, titrated to an effective dose (producing effective relief of all BTP episodes on 2 consecutive days) of 100 to 800 μg. Results:  A total of 270 patients entered the titration phase. Mean (SD) baseline BTP opioid dose was 25.7 (88.9) mg morphine equivalent, and mean baseline around‐the‐clock opioid dose was 196.5 (151.6) mg morphine equivalent. Using conservative criteria for determining effective dose, 174 patients (64.4%) were successfully titrated to an effective dose (mean [SD], 498.2 [234.8] μg). The most frequent (27.6%) effective dose was 800 μg, and more than 85% of patients required an effective dose ≥ 300 μg. There were no significant relationships between any baseline characteristics and titration success. Conclusion:  Despite stringent criteria, 64.4% of patients achieved an effective dose of fentanyl sublingual tablet within the dose range of 100 to 800 μg. Baseline characteristics were not identified to be associated with the likelihood of successful titration or with the actual effective dose of fentanyl sublingual tablet.</description><subject>Administration, Sublingual</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>analgesics</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Breakthrough Pain - drug therapy</subject><subject>Breakthrough Pain - etiology</subject><subject>cancer</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Fentanyl - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - complications</subject><subject>opioid</subject><subject>Tablets - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1530-7085</issn><issn>1533-2500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkMFu1DAQhi0EoqXwCshHLgl2HMcJEodqYVukiFbdFUhcLMeegBcn2ca2uvv29XbLnpnLjOXvn5E-hDAlOU31cZNTzlhWcELyglCaE8ILnu9eoPPTx8unmWSC1PwMvfF-QwgVDWOv0VmRqmKCnqNhFbUG7_vo8JfJA17a0djxN36w4Q9exc6lR1QOL2EMatw7vFadg_AJL6ahsyMYfAc-uuBxP08DLvDNFsasVR0k1IZZBTuNeBWiseDfole9ch7ePfcLtF5-XS-us_bm6tviss10SQTPqK6JaAzrtWi04VpQRWlTlYUhgmjN6rppFDcitZrXrOpZxxot-sKouqINu0Afjmu383QfwQc5WK_BOTXCFL2kpGBJUylYQusjqufJ-xl6uZ3toOZ9guTBtdzIg1J5UCoPruWTa7lL0ffPV2I3gDkF_8lNwOcj8GAd7P97sby9vL1LU8pnx7z1AXanvJr_ykowweXP71fy16ptSfmjlJQ9AiZ1m3U</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Nalamachu, Srinivas R.</creator><creator>Rauck, Richard L.</creator><creator>Wallace, Mark S.</creator><creator>Hassman, David</creator><creator>Howell, Julian</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201207</creationdate><title>Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open-Label Titration Studies</title><author>Nalamachu, Srinivas R. ; Rauck, Richard L. ; Wallace, Mark S. ; Hassman, David ; Howell, Julian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4075-1c8079d3fc79cd5c71a119642d070cc38899a5d789985836f3b39c7f2da86193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Administration, Sublingual</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>analgesics</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Breakthrough Pain - drug therapy</topic><topic>Breakthrough Pain - etiology</topic><topic>cancer</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Fentanyl - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - complications</topic><topic>opioid</topic><topic>Tablets - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nalamachu, Srinivas R.</creatorcontrib><creatorcontrib>Rauck, Richard L.</creatorcontrib><creatorcontrib>Wallace, Mark S.</creatorcontrib><creatorcontrib>Hassman, David</creatorcontrib><creatorcontrib>Howell, Julian</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pain practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nalamachu, Srinivas R.</au><au>Rauck, Richard L.</au><au>Wallace, Mark S.</au><au>Hassman, David</au><au>Howell, Julian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open-Label Titration Studies</atitle><jtitle>Pain practice</jtitle><addtitle>Pain Pract</addtitle><date>2012-07</date><risdate>2012</risdate><volume>12</volume><issue>6</issue><spage>449</spage><epage>456</epage><pages>449-456</pages><issn>1530-7085</issn><eissn>1533-2500</eissn><abstract>Objective:  This analysis was conducted to determine the likelihood of identifying an effective dose of fentanyl sublingual tablet during the initial titration phase of 2 clinical trials, to characterize the actual effective dose in patients achieving successful titration, and to examine the relationship between baseline characteristics and likelihood of achieving an effective dose. Methods:  Data were derived from 2 clinical trials (Study 1, n = 131; Study 2, n = 139) of fentanyl sublingual tablet in patients with cancer‐associated breakthrough pain (BTP). Both trials comprised a 2‐week titration phase and 12‐month maintenance phase. The initial dose was 100 μg, titrated to an effective dose (producing effective relief of all BTP episodes on 2 consecutive days) of 100 to 800 μg. Results:  A total of 270 patients entered the titration phase. Mean (SD) baseline BTP opioid dose was 25.7 (88.9) mg morphine equivalent, and mean baseline around‐the‐clock opioid dose was 196.5 (151.6) mg morphine equivalent. Using conservative criteria for determining effective dose, 174 patients (64.4%) were successfully titrated to an effective dose (mean [SD], 498.2 [234.8] μg). The most frequent (27.6%) effective dose was 800 μg, and more than 85% of patients required an effective dose ≥ 300 μg. There were no significant relationships between any baseline characteristics and titration success. Conclusion:  Despite stringent criteria, 64.4% of patients achieved an effective dose of fentanyl sublingual tablet within the dose range of 100 to 800 μg. Baseline characteristics were not identified to be associated with the likelihood of successful titration or with the actual effective dose of fentanyl sublingual tablet.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22226371</pmid><doi>10.1111/j.1533-2500.2011.00525.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1530-7085
ispartof Pain practice, 2012-07, Vol.12 (6), p.449-456
issn 1530-7085
1533-2500
language eng
recordid cdi_proquest_miscellaneous_1023533473
source Wiley
subjects Administration, Sublingual
Adult
Aged
Aged, 80 and over
analgesics
Analgesics, Opioid - therapeutic use
Breakthrough Pain - drug therapy
Breakthrough Pain - etiology
cancer
Dose-Response Relationship, Drug
Female
Fentanyl - therapeutic use
Humans
Male
Middle Aged
Neoplasms - complications
opioid
Tablets - therapeutic use
Treatment Outcome
title Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open-Label Titration Studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A50%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20Dose%20Finding%20with%20Sublingual%20Fentanyl%20Tablet:%20Combined%20Results%20from%202%20Open-Label%20Titration%20Studies&rft.jtitle=Pain%20practice&rft.au=Nalamachu,%20Srinivas%20R.&rft.date=2012-07&rft.volume=12&rft.issue=6&rft.spage=449&rft.epage=456&rft.pages=449-456&rft.issn=1530-7085&rft.eissn=1533-2500&rft_id=info:doi/10.1111/j.1533-2500.2011.00525.x&rft_dat=%3Cproquest_cross%3E1023533473%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4075-1c8079d3fc79cd5c71a119642d070cc38899a5d789985836f3b39c7f2da86193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1023533473&rft_id=info:pmid/22226371&rfr_iscdi=true